Genetic and environmental risk factors in Parkinson's disease

Clinical Neurology and Neurosurgery

Volumn 100, Issue 1, 1998, Pages 15-26

  Veldman, B A J ^a   Wijn, A M ^a   Knoers, N ^a   Praamstra, P ^a   Horstink, M W I M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Environmental factors; Genetic; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; HERBICIDE; PESTICIDE; UNCLASSIFIED DRUG;

AGE; BRAIN CELL; CELL FUNCTION; ENVIRONMENTAL FACTOR; GENETIC RISK; HEAD INJURY; HUMAN; PARKINSON DISEASE; PHENOTYPE; REVIEW; RISK FACTOR; SMOKING; SUBSTANTIA NIGRA;

EID: 0031834706     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-8467(98)00009-2     Document Type: Article

References (202)

1. Marsden CD Parkinson's disease. J Neurol Neurosurg Psychiatry. 57:1994;672-681.
2. Gibb WR, Lees AJ The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 51:1988;745-752.
3. Riederer P, Wuketich S Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm. 38:1976;277-301.
4. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 119:1996;585-591.
5. Jankovic J Parkinsonism-plus syndromes. Mov Disord. 4(S1):1989;95-119.
6. Rajput AH Frequency and cause of Parkinson's disease. Can J Neurol Sci. 19:1992;103-107.
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 55:1992;181-184.
8. Gibb WR, Lees AJ Anatomy, pigmentation, ventral and dorsal sub-populations of the substantia nigra and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry. 54:1991;388-396.
9. McGeer PL, McGeer EG, Suzuki JS Aging and extrapyramidal function. Arch Neurol. 34:1977;33-35.
10. Thiessen B, Rajput AH, Laventy W, Desai HB Age, environments and the number of substantia nigra neurons. Streifler MB, Korczyn AD, Melamed E, Youdim MBH Advances in Neurology. 1990;201-206 Raven Press, New York.
11. Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem. 58:1992;642-648.
12. Fearnley JM, Lees AJ Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 114:1991;2283-2301.
13. Wolters EC, Calne DB Is Parkinson's disease related to aging? Calne DB Parkinsonism and Aging. 1989;125-132 Raven Press, New York.
14. Scherman D, Desnos C, Darchen F, Pollak P, Javoy Agid F, Agid Y et al. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol. 26:1989;551-557.
15. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet. 2:1985;1213-1216.
16. Steventon GB, Heafield MT, Waring RH, Williams AC Xenobiotic metabolism in Parkinson's disease. Neurology. 39:1989;883-887.
17. Tanner CM Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look. Neurology. 41:1991;89-91.
18. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet. 339:1992;1017-1018.
19. Tanner CM, Langston JW Do environmental toxins cause Parkinson's disease? A critical review. Neurology. 40:1990;17-30.
20. Koller W, Vetere Overfield B, Gray C et al. Environmental risk factors in Parkinson's disease. Neurology. 40:1990;1218-1221.
21. Langston JW, Ballard P, Tetrud JW, Irwin I Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
22. Tipton KF, Singer TP Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem. 61:1993;1191-1206.
23. Tanner CM The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci. 12:1989;49-54.
24. Tanner CM, Chen B, Wang WZ et al. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci. 14:1987;419-423.
25. Li SC, Schoenberg BS, Wang CC, Cheng XM, Rui DY, Bolis CL, Schoenberg DG A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol. 42:1985;655-657.
26. Tanner CM, Chen B, Wang W et al. Environmental factors and Parkinson's disease: a case-control study in China. Neurology. 39:1989;660-664.
27. Goldsmith JR, Herishanu Y, Abarbanel JM, Weinbaum Z Clustering of Parkinson's disease points to environmental etiology. Arch Environ Health. 45:1990;88-94.
28. Calne S, Schoenberg B, Martin W, Uitti RJ, Spencer P, Calne DB Familial Parkinson's disease: possible role of environmental factors. Can J Neurol Sci. 14:1987;303-305.
29. Lux WE, Kurtzke JF Is Parkinson's disease acquired? Evidence from a geographic comparison with multiple sclerosis. Neurology. 37:1987;467-471.
30. Betemps EJ, Buncher CR Birthplace as a risk factor in motor neurone disease and Parkinson's disease. Int J Epidemiol. 22:1993;898-904.
31. Lanska DJ The geographic distribution of Parkinson's disease mortality in the United States. J Neurol Sci. 150:1997;63-70.
32. Hertzman C, Wiens M, Snow B, Kelly S, Calne D A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord. 9:1994;69-75.
33. Schoenberg BS, Osuntokun BO, Adeuja AO, Bademosi O, Nottidge V, Anderson DW, Haerer AF Comparison of the prevalence of Parkinson's disease in black populations in the rural United States and in rural Nigeria: door-to-door community studies. Neurology. 38:1988;645-646.
34. Schoenberg BS, Anderson DW, Haerer AF Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology. 35:1985;841-845.
35. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology. 46:1996;1044-1050.
36. Marttila RJ, Kaprio J, Koskenvuo M, Rinne UK Parkinson's disease in a nationwide twin cohort. Neurology. 38:1988;1217-1219.
37. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology. 33:1983;815-824.
38. Bharucha NE, Stokes L, Schoenberg BS et al. A case-control study of twin pairs discordant for Parkinson's disease: a search for environmental risk factors. Neurology. 36:1986;284-288.
39. Duvoisin RC, Eldridge R, Williams A, Nutt J, Calne D Twin study of Parkinson disease. Neurology. 31:1981;77-80.
40. Marsden CD Parkinson's disease in twins. J Neurol Neurosurg Psychiatry. 50:1987;105-106.
41. Vieregge P, Schiffke KA, Friedrich HJ, Muller B, Ludin HP Parkinson's disease in twins. Neurology. 42:1992;1453-1461.
42. Johnson WG, Hodge SE, Duvoisin R et al. Twin studies and the genetics of Parkinson's disease - a reappraisal. Mov Disord. 5:1990;187-194.
43. Sommer SS, Rocca WA Prion analogues and twin studies in Parkinson's disease. Neurology. 46:1996;273-275.
44. 18F-dopa and positron emission tomography. Neurology. 42:1992;1894-1900.
45. Holthoff VA, Vieregge P, Kessler J et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 36:1994;176-182.
46. Golbe LI The genetics of Parkinson's disease: a reconsideration. Neurology. 40:1990;7-14.
47. Semchuk KM, Love EJ, Lee RG Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology. 43:1993;1173-1180.
48. Schoenberg BS Environmental risk factors for Parkinson's disease: the epidemiologic evidence. Can J Neurol Sci. 14:1987;407-413.
49. Wong GF, Gray CS, Hassanein RS, Koller WC Environmental risk factors in siblings with Parkinson's disease. Arch Neurol. 48:1991;287-289.
50. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC Risk factors for Parkinson's disease. Neurology. 43:1993;1693-1697.
51. Duvoisin RC On heredity, twins and Parkinson's disease. Ann Neurol. 19:1986;409-411.
52. De Michele G, Filla A, Volpe G et al. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. Mov Disord. 11:1996;17-23.
53. Lazzarini AM, Myers RH, Zimmerman TRJ et al. A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology. 44:1994;499-506.
54. Bonifati V, Fabrizio E, Vanacore N, De Mari M, Meco G Familial Parkinson's disease: a clinical genetic analysis. Can J Neurol Sci. 22:1995;272-279.
55. Wood N Genes and Parkinsonism. J Neurol Neurosurg Psychiatry. 62:1997;305-309.
56. Seidler A, Hellenbrand W, Robra BP et al. Possible environmental, occupational and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology. 46:1996;1275-1284.
57. Uitti RJ, Shinotoh H, Hayward M, Schulzer M, Mak E, Calne DB Familial Parkinson's disease' - a case-control study of families. Can J Neurol Sci. 24:1997;127-132.
58. Payami H, Larsen K, Bernard S, Nutt J Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol. 36:1994;659-661.
59. Marder K, Tang MX, Mejia H et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology. 47:1996;155-160.
60. Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC A large kindred with autosomal dominant Parkinson's disease. Ann Neurol. 27:1990;276-282.
61. Waters CH, Miller CA Autosomal dominant Lewy body Parkinsonism in a four-generation family. Ann Neurol. 35:1994;59-64.
62. Bhatia KP, Daniel SE, Marsden CD Familial Parkinsonism with depression: a clinicopathological study. Ann Neurol. 34:1993;842-847.
63. Maraganore DM, Harding AE, Marsden CD A clinical and genetic study of familial Parkinson's disease. Mov Disord. 6:1991;205-211.
64. Markopoulou K, Wszolek ZK, Pfeiffer RF A Greek-American kindred with autosomal dominant, levodopa-responsive Parkinsonism and anticipation. Ann Neurol. 38:1995;373-378.
65. Plante Bordeneuve V, Taussig D, Thomas F, Ziegler M, Said G A clinical and genetic study of familial cases of Parkinson's disease. J Neurol Sci. 133:1995;164-172.
66. Golbe LI, Lazzarini AM, Schwarz KO, Mark MH, Dickson DW, Duvoisin RC Autosomal dominant Parkinsonism with benign course and typical Lewy-body pathology. Neurology. 43:1993;2222-2227.
67. Golbe LI, Di Iorio G, Sanges G, Lazzarini AM, La Sala S, Bonavita V, Duvoisin RC Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol. 40:1996;767-775.
68. Polymeropoulos MH, Higgins JJ, Golbe LI et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 274:1996;1197-1199.
69. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
70. Iwai A, Masliah E, Yoshimoto M et al. The precursor protein of non-A β component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 14:1995;467-475.
71. Heintz N, Zoghbi H A-synuclein - a link between Parkinson and Alzheimer disease? Nat Genet. 16:1997;325-327.
72. Scott WK, Stajich JM, Yamaoka LH Genetic complexity and Parkinson's disease. Science. 277:1997;387-388.
73. Zareparsi S, Kay J, Camicioli R et al. Analysis of the α-synuclein G209A mutation in familial Parkinson's disease. Lancet. 351:1998;37-38.
74. Zareparsi S, Kay J, Camicioli R et al. Modulation of the age at onset of Parkinson's disease by Apolipoprotein E genotype. Ann Neurol. 42:1997;655-658.
75. Swerdlow RH, Parks JK, Miller SW et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol. 40:1996;663-671.
76. Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J Neurochem. 55:1990;1810-1812.
77. Bandmann O, Sweeney MG, Daniel SE, Marsden CD, Wood NW Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. J Neurol. 244:1997;262-265.
78. Mann VM, Cooper JM, Schapira AH Quantitation of a mitochondrial DNA deletion in Parkinson's disease. FEBS. Lett. 299:1992;218-222.
79. Shoffner JM, Brown MD, Torroni A et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics. 17:1993;171-184.
80. Schapira AH, Holt IJ, Sweeney M, Harding AE, Jenner P, Marsden CD Mitochondrial DNA analysis in Parkinson's disease. Mov Disord. 5:1990;294-297.
81. Ikebe S, Tanaka M, Ozawa T Point mutations of mitochondrial genome in Parkinson's disease. Brain Res Mol Brain Res. 28:1995;281-295.
82. Ozawa T, Tanaka M, Ikebe S, Ohno K, Kondo T, Mizuno Y Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. Biochem Biophys Res Commun. 172:1990;483-489.
83. Wooten GF, Currie LJ, Bennett JP, Harrison MB, Trugman JM, Parker WDJ Maternal inheritance in Parkinson's disease. Ann Neurol. 41:1997;265-268.
84. Gasser T, Wszolek ZK, Trofatter J et al. Genetic linkage studies in autosomal dominant Parkinsonism: evaluation of seven candidate genes. Ann Neurol. 36:1994;387-396.
85. Parboosingh JS, Rousseau M, Rogan F et al. Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. Arch Neurol. 52:1995;1160-1163.
86. Bandmann O, Davis MB, Marsden CD, Harding AE Sequence of the superoxide dismutase 1 (SOD 1) gene in familial Parkinson's disease. J Neurol Neurosurg Psychiatry. 59:1995;90-91.
87. Diederich N, Hilger C, Goetz CG, Keipes M, Hentges F, Vieregge P, Metz H Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol. 40:1996;463-465.
88. Plante Bordeneuve V, Taussig D, Thomas F, Said G, Wood NW, Marsden CD, Harding AE Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology. 48:1997;1589-1593.
89. Nanko S, Ueki A, Hattori M et al. No allelic association between Parkinson's disease and dopamine D2, D3 and D4 receptor gene polymorphisms. Am J Med Genet. 54:1994;361-364.
90. Wilhelmsen K, Mirel D, Marder K et al. Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? Ann Neurol. 41:1997;813-817.
91. Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet. 350:1997;1136-1139.
92. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol. 33:1993;368-372.
93. de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, Hofman A Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology. 45:1995;2143-2146.
94. Zhang ZX, Roman GC Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology. 12:1993;195-208.
95. Gudmundsson KR A clinical survey of Parkinsonism in Iceland. Acta Neurol Scand. 43(S33):1967;1-61.
96. Ben Shlomo Y How far are we in understanding the cause of Parkinson's disease? J Neurol Neurosurg Psychiatry. 61:1996;4-16.
97. Wermuth L, Joensen P, Bunger N, Jeune B High prevalence of Parkinson's disease in the Faroe islands. Neurology. 49:1997;426-432.
98. de Rijk MC, Tzourio C, Breteler MM et al. Prevalence of Parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 62:1997;10-15.
99. Jendroska K, Olasode BJ, Daniel SE et al. Incidental Lewy body disease in black Africans. Lancet. 344:1994;882-883.
100. Rajput AH, Offord KP, Beard CM, Kurland LT Epidemiology of Parkinsonism: incidence, classification and mortality. Ann Neurol. 16:1984;278-282.
101. Lilienfeld DE, Chan E, Ehland J, Godbold J, Landrigan PJ, Marsh G, Perl DP Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol. 47:1990;731-734.
102. Stern M, Dulaney E, Gruber SB et al. The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. Arch Neurol. 48:1991;903-907.
103. Cardoso F, Jankovic J Peripherally induced tremor and Parkinsonism. Arch Neurol. 52:1995;263-270.
104. Factor SA, Sanchez Ramos J, Weiner WJ Trauma as an etiology of Parkinsonism: a historical review of the concept. Mov Disord. 3:1988;30-36.
105. Koller WC, Wong GF, Lang A Post-traumatic movement disorders: a review. Mov Disord. 4:1989;20-36.
106. Hofman A, Collette HJ, Bartelds AI Incidence and risk factors of Parkinson's disease in The Netherlands. Neuroepidemiology. 8:1989;296-299.
107. Morano A, Jimenez Jimenez FJ, Molina JA, Antolin MA Risk-factors for Parkinson's disease: case-control study in the province of Caceres. Spain Acta Neurol Scand. 89:1994;164-170.
108. Williams DB, Annegers JF, Kokmen E, O'Brien PC, Kurland LT Brain injury and neurologic sequelae: a cohort study of dementia, Parkinsonism and amyotrophic lateral sclerosis. Neurology. 41:1991;1554-1557.
109. de Rijk MC. Epidemiology of Parkinson's disease. The Rotterdam Study, Thesis. Rotterdam: Erasmus University, 1997.
110. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG Environmental antecedents of young-onset Parkinson's disease. Neurology. 43:1993;1150-1158.
111. Hertzman C, Wiens M, Bowering D, Snow B, Calne D Parkinson's disease: a case-control study of occupational and environmental risk factors. Am J Int Med. 17:1990;349-355.
112. Haack DG, Baumann RJ, McKean HE, Jameson HD, Turbek JA Nicotine exposure and Parkinson disease. Am J Epidemiol. 114:1981;191-200.
113. Grandinetti A, Morens DM, Reed D, MacEachern D Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol. 139:1994;1129-1138.
114. Morens DM, Grandinetti A, Reed D, White LR, Ross GW Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology. 45:1995;1041-1051.
115. Martyn CN, Osmond C Parkinson's disease and the environment in early life. J Neurol Sci. 132:1995;201-206.
116. Mayeux R, Tang MX, Marder K, Cote LJ, Stern Y Smoking and Parkinson's disease. Mov Disord. 9:1994;207-212.
117. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology. 48:1997;1583-1588.
118. Baron JA Cigarette smoking and Parkinson's disease. Neurology. 36:1986;1490-1496.
119. Fowler JS, Volkow ND, Wang GJ et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736.
120. Yong VW, Perry TL Monoamine oxidase B, smoking and Parkinson's disease. J Neurol Sci. 72:1986;265-272.
121. Janson AM, Fuxe K, Goldstein M Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin Investig. 170:1992;232-238.
122. Schwartz RD, Kellar KJ Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science. 220:1983;214-216.
123. Kirch DG, Alho AM, Wyatt RJ Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia. Cell Mol Neurobiol. 8:1988;285-291.
124. Harrison PJ, Pearson RCA Environmental toxins and Parkinson's disease (letter). Trends Neurosci. 12:1989;182.
125. Sasco AJ, Paffenbarger RSJ Smoking and Parkinson's disease. Epidemiology. 1:1990;460-465.
126. Rajput AH, Offord KP, Beard CM, Kurland LT A case-control study of smoking habits, dementia and other illnesses in idiopathic Parkinson's disease. Neurology. 37:1987;226-232.
127. Golbe LI, Cody RA, Duvoisin RC Smoking and Parkinson's disease. Search for a dose-response relationship. Arch Neurol. 43:1986;774-778.
128. Ho SC, Woo J, Lee CM Epidemiologic study of Parkinson's disease in Hong Kong. Neurology. 39:1989;1314-1318.
129. Riggs JE The 'protective' influence of cigarette smoking on Alzheimer's and Parkinson's diseases. Quagmire or opportunity for neuroepidemiology? Neurol Clin. 14:1996;353-358.
130. Morens DM, Grandinetti A, Davis JW, Ross GW, White LR, Reed D Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson disease. Am J Epidemiol. 144:1996;400-404.
131. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA Nicotine activates and desensitizes midbrain dopamine neurons. Nature. 390:1997;401-404.
132. Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol. 39:1996;89-94.
133. Golbe LI, Farrell TM, Davis PH Case-control study of early life dietary factors in Parkinson's disease. Arch Neurol. 45:1988;1350-1353.
134. Golbe LI, Farrell TM, Davis PH Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord. 5:1990;66-70.
135. de Rijk MC, Breteler MM, den Breeijen JH, Launer LJ, Grobbee DE, van der Meche FG, Hofman A Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol. 54:1997;762-765.
136. Scheider WL, Hershey LA, Vena JE et al. Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov Disord. 12:1997;190-196.
137. Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake. Neurology. 46:1996;1270-1274.
138. Vieregge P, von Maravic C, Friedrich HJ Life-style and dietary factors early and late in Parkinson's disease. Can J Neurol Sci. 19:1992;170-173.
139. Hellenbrand W, Boeing H, Robra BP et al. Diet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 47:1996;644-650.
140. Fernandez Calle P, Molina JA, Jimenez Jimenez FJ et al. Serum levels of α-tocopherol (vitamin E) in Parkinson's disease. Neurology. 42:1992;1064-1066.
141. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36.
142. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl J Med 1993;328:176-183.
143. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa, Ann Neurol 1996;39:37-45.
144. Fernandez Calle P, Jimenez Jimenez FJ, Molina JA et al. Serum levels of ascorbic acid (vitamin C) in patients with Parkinson's disease. J Neurol Sci. 118:1993;25-28.
145. Jimenez Jimenez FJ, Molina JA, Fernandez Calle P et al. Serum levels of vitamin A in Parkinson's disease. J Neurol Sci. 111:1992;73-76.
146. Perry TL, Jones K, Hansen S, Wall RA 2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease. J Neurol Sci. 85:1988;309-317.
147. Rabey JM, Vered Y, Shabtai H, Graff E, Harsat A, Korczyn AD Broad bean (Vicia faba) consumption and Parkinson's disease. Adv Neurol. 60:1993;681-684.
148. Rajput AH, Uitti RJ, Stern W et al. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci. 14:1987;414-418.
149. Thiessen B, Rajput AH, Laverty W, Desai H Age, environments and the number of substantia nigra neurons. Adv Neurol. 53:1990;201-206.
150. Svenson LW, Platt GH, Woodhead SE Geographic variations in the prevalence rates of Parkinson's disease in Alberta. Can J Neurol Sci. 20:1993;307-311.
151. Semchuk KM, Love EJ, Lee RG Parkinson's disease and exposure to rural environmental factors: a population based case-control study. Can J Neurol Sci. 18:1991;279-286.
152. Jimenez Jimenez FJ, Mateo D, Gimenez Roldan S Exposure to well water and pesticides in Parkinson's disease: a case-control study in the Madrid area. Mov Disord. 7:1992;149-152.
153. Zayed J, Ducic S, Campanella G, Panisset JC, Andre P, Masson H, Roy M Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci. 17:1990;286-291.
154. Herishanu YO, Goldsmith JR, Abarbanel JM, Weinbaum Z Clustering of Parkinson's disease in southern Israel. Can J Neurol Sci. 16:1989;402-405.
155. Rajput AH, Uitti RJ, Stern W, Laverty W Early onset Parkinson's disease in Saskatchewan - environmental considerations for etiology. Can J Neurol Sci. 13:1986;312-316.
156. Snyder SH, D'Amato RJ Predicting Parkinson's disease. Nature. 317:1985;198-199.
157. Sanchez Ramos JR, Hefti F, Weiner WJ Paraquat and Parkinson's disease. Neurology. 37:1987;728.
158. Snyder SH, D'Amato RJ MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. 1985 The George C. Cotzias lecture. Neurology. 36:1986;250-258.
159. Perry TL, Yong VW, Wall RA, Jones K Paraquat and two endogenous analogues of the neurotoxic substance N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine do not damage dopaminergic nigrostriatal neurons in the mouse. Neurosci Lett. 69:1986;285-289.
160. Koller WC Paraquat and Parkinson's disease. Neurology. 36:1986;1147.
161. Semchuk KM, Love EJ, Lee RG Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology. 42:1992;1328-1335.
162. Barbeau A, Roy M, Cloutier T, Plasse L, Paris S Environmental and genetic factors in the etiology of Parkinson's disease. Adv Neurol. 45:1987;299-306.
163. Montgomery EBJ Heavy metals and the etiology of Parkinson's disease and other movement disorders. Toxicology. 97:1995;3-9.
164. Fahn S, Cohen G The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol. 32:1992;804-812.
165. Jenner P, Schapira AH, Marsden CD New insights into the cause of Parkinson's disease. Neurology. 42:1992;2241-2250.
166. Olanow CW An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol. 32:1992;2-9.
167. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AH Complex I, iron and ferritin in Parkinson's disease substantia nigra. Ann Neurol. 36:1994;876-881.
168. Dexter DT, Sian J, Rose S et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol. 35:1994;38-44.
169. Calne DB, Chu NS, Huang CC, Lu CS, Olanow W Manganism and idiopathic Parkinsonism: similarities and differences. Neurology. 44:1994;1583-1586.
170. Yasui M, Kihira T, Ota K Calcium, magnesium and aluminum concentrations in Parkinson's disease. Neurotoxicology. 13:1992;593-600.
171. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ Occupational exposures to metals as risk factors for Parkinson's disease. Neurology. 48:1997;650-658.
172. Rybicki BA, Johnson CC, Uman J, Gorell JM Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov Disord. 8:1993;87-92.
173. Jimenez Jimenez FJ, Fernandez Calle P, Martinez Vanaclocha M, Herrero E, Molina JA, Vazquez A, Codoceo R Serum levels of zinc and copper in patients with Parkinson's disease. J Neurol Sci. 112:1992;30-33.
174. Gazzaniga GC, Ferraro B, Camerlingo M, Casto L, Viscardi M, Mamoli A A case control study of CSF copper, iron and manganese in Parkinson disease. Ital J Neurol Sci. 13:1992;239-243.
175. Youdim MB, Ben Shachar D, Riederer P The role of monoamine oxidase, iron-melanin interaction and intracellular calcium in Parkinson's disease. J Neural Transm. S32:1990;239-248.
176. Garcia Ruiz PJ, Garcia de Yebenes J, Jimenez Jimenez FJ, Vazquez A, Garcia Urra D, Morales B Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol. 15:1992;19-26.
177. Veitch K, Hue L Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for Parkinsonism. Mol Pharmacol. 45:1994;158-163.
178. Reinhardt JW Side-effects: mercury contribution to body burden from dental amalgam. Adv Dent Res. 6:1992;110-113.
179. Ngim CH, Devathasan G Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. Neuroepidemiology. 8:1989;128-141.
180. Weiner J, Nylander M, Berglund F Does mercury from amalgam restorations constitute a health hazard? Sci Total Environ. 99:1990;1-22.
181. Duvoisin RC, Yahr MD Encephalitis and Parkinsonism. Arch Neurol. 12:1965;227-239.
182. Poskanzer DC, Schwab RS Cohort analysis of Parkinson's syndrome evidence for a single etiology related to sub-clinical infection about 1920. J Chronic Dis. 16:1963;961-973.
183. Picard F, de Saint Martin A, Salmon E, Hirsch E, Marescaux C Post-encephalitic stereotyped involuntary movements responsive to L-Dopa. Mov Disord. 11:1996;567-570.
184. Mellon AF, Appleton RE, Gardner Medwin D, Aynsley Green A Encephalitis lethargica-like illness in a 5-year-old. Dev Med Child Neurol. 33:1991;158-161.
185. Elizan TS, Casals J, Swash M No viral antigens detected in brain tissue from a case of acute encephalitis lethargica and another case of post-encephalitic Parkinsonism. J Neurol Neurosurg Psychiatry. 52:1989;800-801.
186. Howard RS, Lees AJ Encephalitis lethargica. A report of four recent cases. Brain. 110:1987;19-33.
187. Takahashi M, Yamada T, Nakajima S, Nakajima K, Yamamoto T, Okada H The substantia nigra is a major target for neurovirulent influenza A virus. J Exp Med. 181:1995;2161-2169.
188. Sasco AJ, Paffenbarger RSJ Measles infection and Parkinson's disease. Am J Epidemiol. 122:1985;1017-1031.
189. Goto A A follow-up study of Japanese B encephalitis. Psychiatr Neurol JP. 64:1962;236-266.
190. Mulder DW, Parrott M, Thaler M Sequelae of western equine encephalitis. Neurology. 1:1951;318-327.
191. Emard JF, Thouez JP, Gauvreau D Neurodegenerative diseases and risk factors: a literature review. Soc Sci Med. 40:1995;847-858.
192. Mattock C, Marmot M, Stern G Could Parkinson's disease follow intra-uterine influenza?: a speculative hypothesis. J Neurol Neurosurg Psychiatry. 51:1988;753-756.
193. Elizan TS, Madden DL, Noble GR et al. Viral antibodies in serum and CSF of Parkinsonian patients and controls. Arch Neurol. 36:1979;529-534.
194. Marttila RJ, Arstila P, Nikoskelainen J, Halonen PE, Rinne UK Viral antibodies in the sera from patients with Parkinson disease. Eur Neurol. 15:1977;25-33.
195. Calne DB, Langston JW Aetiology of Parkinson's disease. Lancet. 2:1983;1457-1459.
196. Vingerhoets FJ, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol. 36:1994;765-770.
197. Koller WC, Langston JW, Hubble JP et al. Does a long preclinical period occur in Parkinson's disease? Geriatrics. 46(S1):1991;8-15.
198. Gonera EG, Van't Hof M, Berger HJC, Van Weel C, Horstink MWIM. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord. 12:1997;871-876.
199. Leenders KL Pathophysiology of movement disorders studied using PET. J Neural Transm. S50:1997;39-46.
200. Semchuk KM, Love EJ Effects of agricultural work and other proxy-derived case-control data on Parkinson's disease risk estimates. Am J Epidemiol. 141:1995;747-754.
201. Gibb WR, Lees AJ A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology. 38:1988;1402-1406.
202. Golbe LI Young-onset Parkinson's disease: a clinical review. Neurology. 41:1991;168-173.